Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A/B liver function: a real-world multicenter retrospective study
Sin/Bev demonstrated encouraging short-term anti-tumor activity in HCC of CP-A and CP-B, while survival outcomes were affected by differences in hepatic function. Although the regimen was generally well tolerated, patients with impaired liver reserve require vigilant monitoring and comprehensive supportive strategies to maximize therapeutic outcomes.
Authors
- Shuang Xiao (ORCID: https://orcid.org/0000-0001-8171-0714)
- Yuanxu Zhang (ORCID: https://orcid.org/0000-0002-5833-6346)
- Weifeng Zhao (ORCID: https://orcid.org/0000-0001-5905-1396)
- Xiucheng Pan (ORCID: https://orcid.org/0000-0001-9706-9458)
- Wei Sun (ORCID: https://orcid.org/0000-0001-9401-2827)
- Yang Li (ORCID: https://orcid.org/0000-0003-0735-8446)
- Youhan Miao
- Xia Wang (ORCID: https://orcid.org/0000-0003-2266-5137)
- Jinjing Wang (ORCID: https://orcid.org/0000-0002-3777-745X)
- Shengwei Lu
- Yixing Yu (ORCID: https://orcid.org/0000-0001-6895-962X)
Institutions
- Xuzhou Medical College (CN)
- Nantong University (CN)
- Soochow University (CN)
- Second People's Hospital of NanTong (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Wuxi Third People's Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/fonc.2025.1681663
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Soochow University